Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Spermidine/spermine N1-acetyl transferase activity in rat brain following transient focal cerebral ischemia and reperfusion.

Authors: Nagesh Babu, G  Sailor, KA  Sun, D  Dempsey, RJ 
Citation: Nagesh Babu G, etal., Neurosci Lett. 2001 Mar 2;300(1):17-20.
Pubmed: (View Article at PubMed) PMID:11172929

The polyamine system is very sensitive to different pathological states of brain and is perturbed after central nervous system (CNS) injury. Spermidine/Spermine N(1)-acetyl transferase (SSAT) is the key enzyme responsible for interconversion of spermine and spermidine to spermidine and putrescine respectively. In the present study, SSAT activity was evaluated in the rat CNS, following transient focal cerebral ischemia and reperfusion. The middle cerebral artery (MCA) was occluded for 2 h in male spontaneously hypertensive rats by an intraluminal suture technique. Animals were sacrificed at 3-24 h reperfusion following the MCA occlusion and SSAT activity was assayed in cortex and striatum. Results showed that SSAT activity was significantly increased at 12 h reperfusion in cortex and at 9, 12 and 18 h reperfusion in striatum following ischemia compared to sham or contralateral controls. These results demonstrate that polyamine catabolism in the rat CNS is altered following MCA occlusion. In the in vitro ischemia study, SSAT activity was evaluated in primary cortical neuronal cultures at 6-24 h re-oxygenation intervals following oxygen-glucose deprivation for 1 h, and the results from this group show that the enzyme activity increased by about 62% (P<0.05) at 24 h re-oxygenation. This study suggests that the increased SSAT activity may contribute to the increase in putrescine during the post-ischemic period.


Gene Ontology Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 1599544
Created: 2007-02-07
Species: All species
Last Modified: 2007-02-07
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.